PHILADELPHIA, PA — Proscia® has been named to Fierce Medtech’s prestigious “Fierce 15” list for 2025. The annual list highlights privately held companies that are making remarkable advancements in healthcare innovation. Proscia earned this recognition for its pioneering work in AI-driven pathology within the precision medicine ecosystem.
Driving Pathology Innovation with Concentriq®
Central to Proscia’s success is its flagship product, the Concentriq® platform. This comprehensive AI pathology solution spans applications from drug discovery to diagnostics. Equipped with advanced AI-native features and a wide array of tools for building algorithms, Concentriq streamlines routine workflows for over 12,000 pathologists and scientists worldwide. The platform has become a trusted resource for 16 of the top 20 pharmaceutical companies and diagnostic laboratories that collectively process up to 32,000 patient cases per day using Concentriq.
“AI in pathology is about much more than use case-specific applications and individual foundation models,” said David West, Proscia’s CEO. “We’re equipping both life sciences organizations and diagnostic laboratories to fully harness AI’s potential to rewire pathology and drive precision medicine forward. Fierce Medtech’s recognition validates the impact of our broad approach for our users and patients.”
Notable Milestones
Proscia’s inclusion in the Fierce 15 comes amid several significant achievements. Just last week, Labcorp announced it has adopted the Concentriq LS platform to accelerate clinical trials and develop companion diagnostics as part of its extended precision oncology initiatives.
The company has also launched Concentriq Embeddings, designed to speed AI development with foundation models, delivering a 13x efficiency gain. Another recent development includes Proscia’s real-world data offering, which gives data scientists access to a massive repository of over 10 million pathology images integrated with clinical and genomic data for AI-driven insights.
Positioned for Growth
This recognition follows a $50 million funding round announced in March, led by Insight Partners. The additional capital is fueling Proscia’s efforts to further integrate AI into Concentriq’s core functionalities and expand the platform commercially. Currently, Concentriq supports more than 120 research and diagnostic applications, with ambitious plans to grow its portfolio within the precision medicine arena.
Transforming Precision Medicine
From improving pathologist workflows to accelerating insights in precision oncology, Proscia has solidified its role as a major force in healthcare technology. The company’s advancements demonstrate the growing potential for AI to fundamentally change how pathology supports patient care and drug development.
Fierce Medtech’s inclusion of Proscia in the 2025 “Fierce 15” underscores the company’s transformative impact on the healthcare landscape and its unwavering commitment to advancing precision medicine. Proscia continues to set new benchmarks in AI innovation as it propels the field of digital pathology forward.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.